End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.98 ZAR | +1.35% | +6.05% | +7.46% |
02-23 | South Africa's Dis-Chem sales rise 12.2% on strong retail revenue | RE |
02-23 | Dis-Chem Pharmacies Limited Announces Group Revenue Results for the Period from 1 September 2023 to 28 January 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.86 for the current period. Therefore, the company is undervalued.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- With a 2024 P/E ratio at 28.09 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.46% | 1.49B | C | ||
-29.67% | 10.84B | B | ||
-28.54% | 6.06B | B | ||
+7.42% | 6.04B | C | ||
-11.41% | 5.86B | C+ | ||
-0.73% | 4.69B | D- | ||
+52.19% | 4.29B | - | C | |
-9.42% | 3.61B | B | ||
-13.25% | 3.33B | C- | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DCP Stock
- Ratings Dis-Chem Pharmacies Limited